Development and validation of combined symptom-medication scores for allergic rhinitis.
Bernardo Sousa-PintoLuís Filipe Ribeiro de AzevedoMarek JutelIoana AgacheG Walter CanonicaWienczyslawa CzarlewskiNikolaos G PapadopoulosKarl-Christian BergmannPhilippe DevillierDaniel LauneLudger KlimekAram AntoJosep M AntoPatrik EklundRute AlmeidaAnna BedbrookSinthia Bosnic-AnticevichHelen Annaruth BroughLuisa BrussinoVictoria CardonaThomas CasaleLorenzo CecchiDenis CharpinTomás ChivatoElisio M CostaÁlvaro Augusto CruzStephanie DramburgStephen R DurhamGiulia De FeoRoy Gerth van WijkWystke J FokkensBilun GemiciogluTari HaahtelaMaddalena IllarioJuan Carlos IvancevichVioleta KvedarienePiotr KunaDésirée Erlinda Larenas-LinnemannMichael MakrisEve Mathieu-DupasErik MelénMario Morais-AlmeidaRalph MösgesJoaquim MullolKari Christine NadeauNhân Pham-ThiRobyn O'HehirFrederico S RegateiroSietze ReitsmaBoleslaw SamolinskiAziz SheikhCristiana StellatoAna Todo-BomPeter-Valentin TomazicSanna Toppila-SalmiAntonio ValeroArunas ValiulisMaria Teresa VenturaDana WallaceSusan WasermanArzu YorganciogluGovert De VriesMichiel van EerdPetra ZieglmayerTorsten ZuberbierOliver PfaarJoão Almeida FonsecaJean BousquetPublished in: Allergy (2022)
The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.